drug

mezigdomide

1 story · latest Jul 30, 2026

Status: Investigational
Codes: BMS-986348, CC-92480
Trials: 4 registered trials in coverage

Relationships

Developed by Karyopharm Therapeutics Inc

Developed by Bristol Myers Squibb

Developed by AbbVie

Timeline

Bristol Myers Squibb raises 2026 guidance, cites pipeline progress across four programs

Jul 30Quarterly updateBristol Myers Squibb luspatercept

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.